What Are The Clinical Applications, Parameters, And Protocol Guidelines For Using A 585 Nm Pulsed Dye Laser To Treat Hypertrophic Scars And Keloids? Key Insights For Safe And Effective Treatment

A 585 nm pulsed dye laser (PDL) can improve erythema, vascularity, firmness, pliability, and sometimes thickness in hypertrophic scars and keloids. It works through selective photothermolysis, preferentially heating hemoglobin-rich scar microvasculature while limiting injury to surrounding tissue. Treatment is generally performed in serial sessions with adjacent, non-overlapping pulses; fluence is individualized according to scar thickness, vascularity, skin phototype, and the tissue response.

Core takeaway: PDL is primarily a vascular treatment, not a stand-alone volumetric debulking procedure. Use conservative, device-specific parameters, treat the entire scar systematically, and adjust fluence gradually according to clinical response and adverse effects.

What the 585 nm PDL Treats

Hypertrophic scars

PDL is most useful when hypertrophic scars are red, raised, vascular, pruritic, firm, or symptomatic. It can reduce redness and may improve scar height, stiffness, and pliability over multiple treatments.

The reference describes approximately 50–80% clinical improvement after two sessions in typical hypertrophic scars, although results vary substantially with scar age, thickness, vascularity, location, and patient biology.

Keloids

Keloids may also respond, particularly when erythema, vascularity, and active growth are prominent. However, dense or longstanding keloids usually require more sessions and combination therapy than uncomplicated hypertrophic scars.

PDL should not be represented as reliably curative for keloids. Recurrence prevention may require adjunctive treatment such as intralesional corticosteroid or another evidence-based scar-management strategy.

Early versus mature scars

Vascular lasers generally have the greatest rationale for erythematous, vascular, and actively remodeling scars. Mature, pale, densely fibrotic scars may respond less predictably because they contain less targetable vascularity.

The clinician should first determine whether the lesion is hypertrophic or keloidal, whether it is still active, and whether symptoms such as pain or pruritus justify treatment.

Core Treatment Parameters

Wavelength and pulse duration

The relevant wavelength is 585 nm, typically delivered by a flashlamp-pumped PDL. Some contemporary systems use 595 nm; those settings should not automatically be transferred to a 585 nm device.

Reported pulse durations range from approximately 450 to 1,500 microseconds, depending on the device, spot size, scar vascularity, and treatment objective. A commonly cited parameter is 450 microseconds, but the manufacturer’s validated settings and the operator’s clinical endpoint take priority.

Fluence and spot size

Common starting ranges for hypertrophic scars include:

5–7 mm spot: approximately 6.0–7.5 J/cm²
10 mm spot: approximately 4.5–5.5 J/cm²
A broader fair-skin range reported in clinical protocols is approximately 3.5–7.5 J/cm², reflecting differences among devices and treatment approaches.

These ranges are starting references, not universal prescriptions. Fluence depends on pulse duration, spot geometry, cooling, device calibration, skin type, and the scar’s thickness and vascularity.

Skin phototype

For Fitzpatrick I–III skin, clinicians can generally begin within the lower part of the appropriate device-specific range and titrate toward the intended endpoint.

For Fitzpatrick IV–VI skin, melanin competes with hemoglobin for laser absorption. A conservative approach includes:

Reducing the initial fluence, often by about 10% or more
Using an appropriately large spot when clinically suitable
Performing a test spot
Allowing adequate observation before treating the entire lesion
Using cooling and strict photoprotection

Fitzpatrick V–VI skin should be treated as higher risk, not automatically excluded in every clinical setting. Some practitioners may reasonably choose non-laser options, particularly when the scar is minimally vascular or the risk of dyschromia outweighs the expected benefit.

Treatment Protocol

Pre-treatment assessment

Document scar height, color, firmness, pliability, symptoms, and dimensions. Record the Fitzpatrick skin type, history of post-inflammatory hyperpigmentation, prior scar treatments, active infection, photosensitizing medications, and any tendency toward abnormal wound healing.

Photographs under consistent lighting are useful for monitoring change. Consider whether the lesion is actually a keloid, hypertrophic scar, dermatofibroma, or another process before treatment.

Test-spot strategy

A test spot is especially important for darker skin phototypes, heavily pigmented skin, uncertain device settings, or patients with a history of post-inflammatory hyperpigmentation.

The test area should be assessed for excessive blistering, prolonged crusting, pigment alteration, and the expected vascular endpoint before full-area treatment.

Pulse placement

Apply serial, adjacent, non-overlapping pulses across the entire scar and treatment margin when clinically appropriate. A systematic pattern reduces untreated gaps and prevents excessive energy accumulation in one area.

Pulse overlap should be avoided unless a specific, validated protocol explicitly requires it. Unintended overlap increases the risk of blistering, crusting, textural change, and secondary scarring.

Clinical endpoint

Transient purpura is a commonly expected endpoint, especially in highly erythematous or vascular scars. The clinician should distinguish acceptable purpura from excessive epidermal injury.

Blistering, marked whitening, extensive crusting, or persistent oozing indicates excessive tissue injury or an inappropriate treatment setting and should prompt lower fluence or reassessment before the next session.

Treatment interval

Reassess patients at approximately 6–8 weeks, allowing acute inflammation to resolve and collagen remodeling to become apparent.

If the scar is improving and treatment is well tolerated, maintain the same energy density. If there is minimal response and no significant adverse reaction, increase fluence cautiously—commonly by approximately 10% at the next session.

If blistering, crusting, or oozing occurs, reduce the energy density rather than increasing it.

Aftercare and Monitoring

Immediate care

After treatment, use the wound-care approach appropriate to the degree of purpura and epidermal disruption. A bland protective ointment may be used when indicated, and patients should avoid picking or traumatizing the treated area.

The patient should receive clear instructions about signs of infection, unexpected pain, blistering, delayed healing, and pigmentary change.

Sun protection

Strict sun protection is essential, particularly for patients prone to hyperpigmentation. Patients should minimize ultraviolet exposure and follow the clinician’s instructions regarding broad-spectrum sunscreen once the skin barrier permits its use.

Follow-up assessment

At each visit, assess:

Scar color and vascularity
Height and firmness
Pliability and range of motion
Pain and pruritus
Pigmentary change
Blistering, crusting, erosion, or delayed healing
Evidence of continued keloid growth or recurrence

PDL should be discontinued or modified if the risk profile becomes unfavorable or if the lesion is not demonstrating a meaningful response.

When PDL Alone Is Not Enough

Dense or bulky scars

PDL targets vascularity more directly than scar volume. A thick, mature, or mechanically restrictive lesion may require another treatment directed at bulk or fibrosis.

Options may include intralesional corticosteroid, other intralesional agents, surgery with recurrence prevention, silicone therapy, pressure therapy, or fractional resurfacing, depending on the location and diagnosis.

Combination treatment

Some protocols combine ablative or fractional resurfacing with vascular laser treatment. This should be considered a specialist protocol, because ablative treatment introduces additional risks of infection, delayed healing, pigment alteration, and scarring.

A combined CO₂–PDL approach should not be treated as a routine extension of standard 585 nm PDL. It requires appropriate equipment, anesthesia and wound-care planning, and a clear rationale for addressing both scar bulk and vascularity.

Understanding the Trade-offs

Results are variable

The reported 50–80% improvement after two sessions should be viewed as an approximate clinical expectation for selected hypertrophic scars, not a guarantee. Keloids, dense scars, and scars with little erythema often respond less predictably.

Purpura is expected, but injury is not

Temporary purpura can be an acceptable vascular endpoint and may last approximately 7–10 days. Blistering, extensive crusting, or oozing suggests excessive thermal exposure and increases the risk of delayed healing and textural or pigmentary complications.

Darker skin requires additional caution

The same wavelength that targets hemoglobin can also interact with epidermal melanin. Patients with darker skin phototypes have increased risk of post-inflammatory hyperpigmentation or hypopigmentation, particularly when fluence is excessive or cooling is inadequate.

There is no universally appropriate single fluence for all skin types or devices. Conservative test treatment and consideration of non-laser options are often prudent.

Do not confuse 585 nm and 595 nm protocols

A protocol developed for a 595 nm system—including its fluence, pulse duration, spot size, or cooling method—should not be copied directly onto a 585 nm device. Laser parameters are platform-specific and must be interpreted in the context of the manufacturer’s operating characteristics.

PDL does not eliminate recurrence risk

Keloids are biologically prone to recurrence. Even when PDL improves redness and pliability, additional preventive or adjunctive treatment may be necessary.

How to Apply This to Clinical Practice

Treatment should be performed by a trained clinician with appropriate eye protection, device-specific training, cooling capability, and a plan for managing pigmentary or wound-healing complications.

If your primary focus is erythema and vascularity: Use serial, adjacent, non-overlapping 585 nm PDL pulses and titrate conservatively toward an appropriate vascular endpoint.
If your primary focus is scar thickness or firmness: Recognize that PDL may be insufficient alone and evaluate adjunctive intralesional, pressure, silicone, surgical, or resurfacing therapies.
If your primary focus is safety in darker skin: Begin conservatively, use a test spot and strict photoprotection, and consider non-laser treatment when dyschromia risk is substantial.
If your primary focus is treatment response: Reassess at 6–8 weeks, maintain fluence when improvement is occurring, and increase it by about 10% only when response is inadequate and adverse effects are absent.
If your primary focus is keloid recurrence: Use PDL as part of a broader recurrence-prevention plan rather than as a stand-alone curative treatment.

With careful patient selection and gradual parameter adjustment, 585 nm PDL can be a useful component of a structured hypertrophic-scar and keloid treatment plan.

Summary Table:

Parameter	Typical Range/Value	Notes
Wavelength	585 nm	Specific to PDL; do not substitute with 595 nm settings
Pulse Duration	450–1500 μs	Commonly 450 μs; use device-specific validated settings
Fluence (5–7 mm spot)	6.0–7.5 J/cm²	Starting range; adjust based on response
Fluence (10 mm spot)	4.5–5.5 J/cm²	Conservative starting range
Test Spot	Recommended	Especially for darker skin types or uncertain settings
Treatment Interval	6–8 weeks	Allow for remodeling and resolution of purpura
Clinical Endpoint	Transient purpura	Avoid blistering or crusting; indicates excessive injury
Adjustment	Increase ~10% if no response; decrease if adverse effects	Slow titration for safety
Skin Phototype	I–III: lower range; IV–VI: reduce fluence ~10%, test spot, strict photoprotection	Higher risk of dyschromia in darker skin

Elevate Your Scar Treatment with Advanced PDL Technology

At BELIS, we offer professional-grade Pulsed Dye Laser systems designed for clinics and premium salons. Our devices provide precise, safe, and effective treatment for hypertrophic scars and keloids, enhancing patient satisfaction and practice growth.

Why Choose BELIS?

High-Performance Technology: Our PDL devices feature advanced cooling, adjustable parameters, and validated protocols for optimal outcomes.
Comprehensive Portfolio: From PDL to Diode, Alexandrite, CO2, and more, we cover all aesthetic needs.
Training & Support: We provide ongoing education and technical assistance to ensure your team's success.

Ready to expand your services? Contact us today to learn more about our PDL systems and how BELIS can help you deliver exceptional results.

Trust BELIS for innovative, reliable, and effective aesthetic solutions.